1.Comparison of the Toxicities and Efficacies of the Combination Chemotherapy Regimens in Advanced Gastric Cancer Patients Who Achieved Complete Response after Chemotherapy.
Yun Jeung KIM ; Pyung Gohn GOH ; Eui Sik KIM ; Su Youn LEE ; Hee Seok MOON ; Eaum Seok LEE ; Jae Kyu SUNG ; Seok Hyun KIM ; Byung Seok LEE ; Hyun Yong JEONG
The Korean Journal of Gastroenterology 2011;58(6):311-317
BACKGROUND/AIMS: We retrospectively analyzed comparative toxicities and efficacies of chemotherapy regimens in advanced gastric cancer (AGC) patients who achieved complete response (CR) after chemotherapy. METHODS: We reviewed the medical records of 1,203 patients, who were pathologically diagnosed as AGC in a single center between January 2001 and October 2007. On the basis of the Response Evaluation Criteria in Solid Tumors, CR was evaluated with abdominal computed tomography. Toxicities were evaluated using the National Cancer Institute's common toxicity criteria before each chemotherapy cycle. RESULTS: Among the 1,203 AGC patients enrolled in this study, 568 received chemotherapy and 635 received best supportive care. The major chemotherapy regimens were 5-fluorouracil, leucovorin and oxaliplatin (FOLFOX), docetaxel, cisplatin and 5-fluorouracil (DCF) and 5-fluorouracil, leucovorin and irinotecan (FOLFIRI). Among the 568 patients, 51 (9.0%) achieved CR (49 [8.6%] with FOLFOX [n=12], DCF [n=26], or FOLFIRI [n=11] and 2 [0.3%] with etoposide, leucovorin and 5-fluorouracil). For patients administered FOLFOX, DCF, and FOLFIRI, the median time to disease progression was 4 months (range, 1.8-59.5), 15 months (range, 2.9-31.2) and 10 months (range, 2.0-39.5), and the median survival times were 48 months (range, 5.9-74.0), 37 months (range, 14.0-86.0), and 30 months (range, 6.0-50.0), respectively. Grades 3-4 mucositis occurred mostly in patients administered DCF (n=8, 30.8%). Grades 3-4 leucopenia were observed in 1 (8.3%), 11 (42.3%), and 4 (36.4%) patients administered FOLFOX, DCF and FOLFIRI, respectively. No statistically significant differences were observed in the 3 regimens. CONCLUSIONS: All 3 regimens (FOLFOX, DCF and FOLFIRI) were active and tolerable. Their efficacies and toxicities were not significantly different.
Adult
;
Aged
;
Antineoplastic Agents/*therapeutic use/toxicity
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use/toxicity
;
Camptothecin/analogs & derivatives/therapeutic use/toxicity
;
Cisplatin/therapeutic use/toxicity
;
Drug Therapy, Combination
;
Female
;
Fluorouracil/therapeutic use/toxicity
;
Humans
;
Leucovorin/therapeutic use/toxicity
;
Leukopenia/etiology
;
Male
;
Middle Aged
;
Mucositis/etiology
;
Nausea/etiology
;
Neoplasm Staging
;
Organoplatinum Compounds/therapeutic use/toxicity
;
Retrospective Studies
;
Stomach Neoplasms/*drug therapy/mortality
;
Survival Rate
;
Taxoids/therapeutic use/toxicity
;
Tomography, X-Ray Computed
;
Vomiting/etiology
2.Efficacy of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer: a meta-analysis of randomized controlled clinical trials.
Rui HAN ; Guanying WANG ; Yujiao ZHANG ; Xinhan ZHAO
Journal of Zhejiang University. Medical sciences 2016;45(4):379-386
To evaluate the efficacy and safety of neoadjuvant chemotherapy combined with bevacizumab versus neoadjuvant chemotherapy alone for Her2-negative breast cancer.We searched PubMed, the Cochrane Library, Web of Science, CNKI, Wanfang Database and the abstracts of major international conferences in recent 5 years to identify prospective randomized controlled clinical trials that met the inclusion and exclusion criteria. Study selection and analyses were undertaken according to the Cochrane Handbook. Meta-analysis was performed using RevMan 5.3 software.Six trials were identified with 4440 eligible patients. The results of this meta-analysis showed that the rate of pathological complete response (pCR) was higher in Her-2 negative breast cancer patients receiving bevacizumab combined with neoadjuvant chemotherapy than that in patients with neoadjuvant chemotherapy alone (24.7% vs 20.1%,=1.23, 95%:1.10-1.37,<0.01). In addition, the pCR rate rose up when bevacizumab was added to neoadjuvant chemotherapy both in hormone receptor-positive patients (13.1% vs 10.2%,=1.28, 95%:1.04-1.58,<0.05) and in hormone receptor-negative patients (46.3% vs 37.1%,=1.25, 95%:1.12-1.39,<0.01). Statistical differences were observed in the rate of relevant adverse events such as hypertention (3.2% vs 0.6%,=5.292, 95%:2.933-9.549,<0.01) and mucositis (10.5% vs 2.0%,=5.340, 95%:3.743-7.617,<0.01) between the combination group and the chemotherapy alone group. Differences in other toxicities such as febrile neutropenia, infection, surgical complications, neutropenia and hand-foot syndrome were also found to be statistically significant between the combination group and the chemotherapy alone group (all<0.05), while such difference was not found in the occurrence of peripheral neuropathy (>0.05).The addition of bevacizumab to neoadjuvant chemotherapy in Her2-negative breast cancer can significantly improve pathological complete response, but may bring more grade 3 and 4 toxicities.More neoadjuvant trials need to be done to define subgroups of Her2-negative breast cancer that would have clinically significant long-term benefit from bevacizumab treatment.
Antineoplastic Combined Chemotherapy Protocols
;
therapeutic use
;
toxicity
;
Bevacizumab
;
adverse effects
;
therapeutic use
;
toxicity
;
Breast Neoplasms
;
chemistry
;
drug therapy
;
Female
;
Humans
;
Neoadjuvant Therapy
;
adverse effects
;
methods
;
Prospective Studies
;
Receptor, ErbB-2
;
analysis
;
Triple Negative Breast Neoplasms
;
drug therapy
3.The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Se Ryeon LEE ; Deok Hwan YANG ; Jae Sook AHN ; Yeo Kyeoung KIM ; Je Jung LEE ; Young Jin CHOI ; Ho Jin SHIN ; Joo Seop CHUNG ; Yoon Young CHO ; Yee Soo CHAE ; Jong Gwang KIM ; Sang Kyun SOHN ; Hyeoung Joon KIM
Journal of Korean Medical Science 2009;24(3):498-503
A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (> or =500/microL) and platelets (> or =20,000/microL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Cytarabine/*therapeutic use/toxicity
;
Disease-Free Survival
;
Female
;
Granulocyte Colony-Stimulating Factor/*therapeutic use/toxicity
;
Humans
;
Idarubicin/therapeutic use
;
Leukemia, Myeloid, Acute/*drug therapy/mortality
;
Male
;
Middle Aged
;
Recurrence
;
Treatment Outcome
;
Vidarabine/*analogs & derivatives/therapeutic use/toxicity
4.The Clinical Outcome of FLAG Chemotherapy without Idarubicin in Patients with Relapsed or Refractory Acute Myeloid Leukemia.
Se Ryeon LEE ; Deok Hwan YANG ; Jae Sook AHN ; Yeo Kyeoung KIM ; Je Jung LEE ; Young Jin CHOI ; Ho Jin SHIN ; Joo Seop CHUNG ; Yoon Young CHO ; Yee Soo CHAE ; Jong Gwang KIM ; Sang Kyun SOHN ; Hyeoung Joon KIM
Journal of Korean Medical Science 2009;24(3):498-503
A refractory and resistant disease to conventional induction chemotherapy and relapsed disease are considered as the most important adverse prognostic factors for acute myeloid leukemia (AML). Sixty-one patients (median age, 33.6 yr) with relapsed or refractory AML were treated with the FLAG regimen that consisted of fludarabine (30 mg/m2, days 1-5), cytarabine (2.0 g/m2, days 1-5) and granulocyte colony-stimulating factor. Of the treated patients 29 patients (47.5%) achieved complete remission (CR). Higher CR rates were observed for patients with a first or second relapse as compared to patients with a primary refractory response or relapse after stem cell transplantation (HSCT). There was a significant difference in the response rates according to the duration of leukemia-free survival (pre-LFS) before chemotherapy (P=0.05). The recovery time of both neutrophils (> or =500/microL) and platelets (> or =20,000/microL) required a median of 21 and 18 days, respectively. Treatment-related mortality (TRM) occurred in seven patients (11.4%), of which 71.4% of TRM was caused by an invasive aspergillosis infection. After achieving CR, 18 patients underwent consolidation chemotherapy and six patients underwent allogeneic HSCT. In conclusion, FLAG chemotherapy without idarubicin is a relatively effective and well-tolerated regimen for relapsed or refractory AML and the use of FLAG chemotherapy has allowed intensive post-remission therapy including HSCT.
Adult
;
Aged
;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
;
Cytarabine/*therapeutic use/toxicity
;
Disease-Free Survival
;
Female
;
Granulocyte Colony-Stimulating Factor/*therapeutic use/toxicity
;
Humans
;
Idarubicin/therapeutic use
;
Leukemia, Myeloid, Acute/*drug therapy/mortality
;
Male
;
Middle Aged
;
Recurrence
;
Treatment Outcome
;
Vidarabine/*analogs & derivatives/therapeutic use/toxicity